Source document: https://docs-lawep.s3.us-east-2.amazonaws.com/1694831221278.pdf (Georgia)
Cancer in Georgia 2015-2019 National Center for Disease Control and Public Health TABLE OF CONTENT Foreword ........................................................................................................................................................................................... 3 Highlights .......................................................................................................................................................................................... 4 Global data on the cancer morbidity ......................................................................................................................................... 6 Cancer related morbidity and mortality .................................................................................................................................... 7 Top 5 sites of cancer in females ............................................................................................................................................... 18 1.
Breast cancer in females .......................................................................................................................................... 19 2.

Thyroid gland cancer in females ............................................................................................................................ 22 3.

Colorectal cancer in females ................................................................................................................................... 25 4.
Corpus uteri cancer ................................................................................................................................................... 27 5.
Cervix uteri cancer ..................................................................................................................................................... 29 Top 5 sites of cancer in males ..................................................................................................................................... 32 1.

Trachea, bronchus, lung in males .......................................................................................................................... 32 2.
Prostate cancer ........................................................................................................................................................... 36 3.

Bladder cancer in males ........................................................................................................................................... 39 4.
Colorectal cancer in males ...................................................................................................................................... 42 5.
Larinx cancer in males ................................................................................................................................. 44 Cancer in early ages ...................................................................................................................................................... 47 Malignant neoplasms in children aged under-15 ................................................................................................................. 47 Malignant neoplasms in adolescents aged 15–19 years .................................................................................................... 49 Geographic distribution ................................................................................................................................................ 51 Screening of cancer ...................................................................................................................................................... 55 Treatment ....................................................................................................................................................................... 56 Treatment: top 5 sites of cancer in females ........................................................................................................ 57 Treatment: top 5 sites in males ............................................................................................................................. 62 2 FOREWORD National Center for Disease Control and Public Health Cancer Population Register was launched in Georgia on January 1, 2015, this is an important step forward for the country, because the Register provided quality data on the spread of malignant neoplasms in the country.
The Register is a personalized data system.

The registry is functioning for five years, improving data quality and coverage, although there are still some challenges that need to be addressed.

The given document covers data on malignant tumors registered during 2015-2019.

3 HIGHLIGHTS National Center for Disease Control and Public Health  During 2015-2019, in Georgia, the total number of new cases of all sites of cancer (including in situ1 neoplasms) ranges from 10,000 to 11,000.
In 2019, 10,339 new cases of cancer were registered, with the incidence rate of 277.9 per 100,000 population.

 56 56% of new cases of cancer of all localizations were registered in women, 44% - in men.

 68 68% of new cases are registered in the most able-bodied age group (30-70 years); 28% of cases - in the age group of 70 years and older.

1.3% of new cases come from the age groups of 0 - 15 years and 15 - 20 years.
25% of new cases of all sites cancers are registered in women of reproductive age (15-49 years).

 Top 5 sites of cancers in women:  Breast  Thyroid gland  Colorectum  Body of the uterus  Cervix of the uterus.

 Top 5 sites of cancers in men:  Trachea / bronchus / lung  The prostate gland  Bladder  Colorectum  Larynx    In Georgia, like in other countries, leukemia, lymphomas and the brain and spinal cord cancers are the most frequent malignant neoplasms in children.
In 2019, 43% of new cases of all new cases of cancer2 of all sites were registered at stages I and II of the disease; 41% at stages III and IV , for other cases the stage was not identified.

In 2019, in Georgia, there were 7873 cancer.

Among them the leading causes were lung (15%) and breast cancers (10%), cancers of trachea, bronchus, lung, digestive system (excluding stomach and esophagus), lymphoid, haematopoietic and related tissue, and colorectal cancer.
 Georgian Cancer Population Register has been operating since 2015, making possible to calculate 5-year survival rates for cases registered in 2015.

 In Georgia, the five-year survival rate for all cancer sites was 50.1% (calculated using the direct survival assessment method).
1 Preinvasive cancer 2 The number of all new cases does not include cancers of lymphoid, haematopoietic and related tissue 4     In Georgia, the 5-year survival rate of early cancer (age under-20) is high and is about 93% for both sexes.

National Center for Disease Control and Public Health In Georgia, according to the assessment of the US National Cancer Institute (NCI) 3, 51% of the new cancer cases require surgical treatment, 72% chemotherapy, and 57% radiotherapy.
In 2019, according to the Cancer Population Register, surgical treatment was performed in 74% of new cases, chemotherapy and hormone therapy - in 58%, radiation therapy - in 28%, iodine therapy - in 5%, immunotherapy - in 2%.

The share of palliative care was implemented in 4% of the cases.

In Georgia, during the period of 2018-2030, according to international projections, the number of new cases of cancer will increase by 6% (in women - by 5%, in men - by 7%).
During the same period, Europe is projected to see a 14% increase of new cases (10% in women, 18% in men) 4.

3 Human Resources Needed for Cancer Control in Low & Middle Income Countries.

National Cancer Institute.


Radiation Research Program 4 https://gco.iarc.fr/tomorrow/graphic- isotype?type=0&type_sex=0&mode=population&sex=0&populations=935_268&cancers=39&age_group=value&apc_ male=0&apc_female=0&single_unit=500000&print=0#collapse-group-0-3 5 GLOBAL DATA ON THE CANCER MORBIDITY5 National Center for Disease Control and Public Health  In 2018, the global burden of cancer consisted of 18.1 million new cases and 9.6 million deaths.
Worldwide, on average, one in every five men and one in six women has cancer.

The most common sites of cancer are:  Lung cancer (2.09 million cases);  Breast cancer (2.09 million cases);  Colorectal cancer (1.80 million cases);  Prostate cancer (1.28 million cases);  Skin cancer (non-melanoma) (1.04 million cases);  Stomach cancer (1.03 million cases).

 Globally, cancer is the second leading cause of death.
In the world, on average, one in every eight men, and one in every 11 women die from a malignant neoplasm.

A high proportion of cancer deaths is due to the following sites of cancer:  Lung cancer (1.76 million deaths)  Colorectal cancer (862 000 deaths)  Stomach cancer (783 000 deaths)  Liver cancer (782 000 deaths)  Breast cancer (627,000 deaths).

 Globally, the number of patients, staying alive 5 years after diagnosis is 43.8 million.
 About 70% of cancer-related deaths are registered in middle- and low-income countries.

 About 1/3 of cancer-related deaths are caused by top 5 behavioral and dietary risk factors: obesity, inadequate fruit and vegetable consumption, low physical activity, and excessive tobacco and alcohol consumption.

 The most important risk factor for cancer development is tobacco use, with 22% of cancer deaths associated with it.
  In low- and middle-income countries up to 25% of cancer cases are caused by cancer-related infections such as hepatitis B and C and human papillomavirus (HPV).

In countries and regions of the world cancer detection varies with the stages, availability of low-income countries had diagnostic means and pathomorphological diagnostic services available to the population.
In more than 90% of high- income countries cancer treatment is available, when the same service is available in only 30% of low-income countries.

In 2017, only 26% of treatment.

 The economic impact of cancer is significant and it rises.

In 2010, the total economic value / burden of cancer was estimated at approximately 1.16 trillion USD.

 In the group of low- and middle-income countries, on average, one in five countries has the necessary evidence for sound cancer management policies.
5 https://www.who.int/news-room/fact-sheets/detail/cancer 6 CANCER RELATED MORBIDITY AND MORTALITY National Center for Disease Control and Public Health In 2019, in Georgia, 10,339 new cases of all sites cancer were registered, the incidence rate per 100,000 population was 277.9.

Figure 1.

Cancer, incidence per 100000 population 5F 6 Figure 2.
Cancer related mortality Source: WHO HFA DB, NCDC Source: WHO HFA DB, NCDC 6 For international comparisons, other cancer of skin (except melanoma) and in situ cancer cases are not included in the analysis.

according to the recommendation of the International agency for research on cancer (IARC), 7 Table 1.
Cancer, main indicators of morbidity and mortality, Georgia National Center for Disease Control and Public Health Number of cases of cancer, all sites Incidence per 100000 population Number of cases of cancer, all sites except cancer of skin (except melanoma) and cancers in situ Incidence per 100000 population Number of deaths with cancer as underlying cause of death7 Mortality per 100000 population Figure 3.
Cancer, sites with high incidence by sex, Georgia, 2019 The number of cases of the above mentioned sites accounts for 69% of the total number of new cases registered in both sexes.

According to international estimates, the lifetime risk of developing cancer in the Georgian population equals to 40%8.

7 According to the Geostat data 8 DevCan: Developing or Dying of Cancer Software, Version 6.7.7.
Statistical Research and Applications Branch, National Cancer Institute, 2019. surveillance.cancer.gov/devcan/ და https://seer.cancer.gov/ 8 Table 2.
Lifetime risks of developing cancer, Georgia National Center for Disease Control and Public Health Male All sites Prostate Trachea, bronchus, lung Colorectal Melanoma Non-Hodgkin lymphoma Kidney and renal pelvis Leukemia Thyroid gland % 40.1 12.1 6.3 4.2 3.6 2.4 2.2 1.9 0.7 Female All sites Breast Trachea, bronchus, lung Colorectal Corpus uteri Melanoma Non-Hodgkin lymphoma Thyroid gland Leukemia Kidney and renal pelvis Ovary % 38.7 12.9 6.0 4.2 3.1 2.5 1.9 1.3 1.3 1.2 1.2 Cervix uteri 0.6 https://seer.cancer.gov/statfacts/html/common.html (2011 – 2016) Both sexes Bladder Pancreas Lip, mouth and throat Liver and intrahepatic bile ducts Brain Larynx Hodgkin's lymphoma Bone and articular cartilage % 2.4 1.6 1.2 1.0 0.6 0.3 0.2 0.1 9 FIVE YEAR SURVIVAL RATES 8F 9 National Center for Disease Control and Public Health The survival rate is a percentage of people who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease, such as cancer.
The often stated as a five- year survival rate, which is the percentage of people who are alive five years after their diagnosis or the start of treatment.

One-year and five-year survival rates are the most commonly used.

Cancer prevention, early diagnosis, refinement of oncology treatment methods and development of technologies are the cornerstones that lead to an increase of the survival period of the cancer patient.

Direct and indirect (estimated) methods of calculating survival rates are used.
The easiest way to calculate patient’s survival rate is to use a direct method which, as says the definition, shows the percentage of patients who survived at the end of the interested time period (e.g., a five-year period).

This method does not take into account the existing differences in survival in the group of patients during the observation period (eg five years)9F 10.

The Kaplan-Meier method is the most popular among indirect methods of estimating the probability of survival.
For each case (death) it takes into account the moment of detection (which is likely to happen randomly) during the study period (e.g.

5 years) and combines the survival probabilities calculated for subsequent time intervals.

Each time interval, which is mostly unequal, is defined as the time period between two subsequent events (death)11.

According to the concept of survival, after one or five years, the patient will be alive, although the disease may recur or not recur.
The median survival period is the average time interval (from the start of treatment or the time of diagnosis) during which patients survive12.

9 Survival rates in the given document are calculated using the direct method 10 Parkin D.M., Hakulinen T. Analysis of survival.

International Agency for Research on Cancer.


p.163-164 11 A Dictionary of Epidemiology, Sixth Edition, Edited by Miquel Porta, 2015 12 https://stats.oecd.org/Index.aspx?QueryId=51882; https://seer.cancer.gov/statfacts/html/common.html 10 Figure 4.
5 year survival rate for some cancer sites National Center for Disease Control and Public Health Source: Georgian population cancer registry https://stats.oecd.org/Index.aspx?QueryId=51882; https://www.cdc.gov/cancer/dcpc/research/articles/concord-2.htm 11 Table 3.
Five-year survival rates of cancer by sites (%): breast (in women) and cervix uteri, 15 years and older, 2010-2014 National Center for Disease Control and Public Health Breast (females) Cervix uteri USA Australia Japan Iceland Sweden Canada Finland Israel New Zealand Portugal Norway France Korea Netherlands Belgium Switzerland Denmark Germany Italy United Kingdom Spain Austria Slovenia China Turkey Ireland Czechia Estonia Latvia Poland Slovakia Iceland Korea Norway Japan Switzerland Denmark Sweden China Netherlands New Zealand Finland Canada Italy Israel Estonia Australia Portugal Slovenia Belgium Germany France Spain Austria United Kingdom Ireland USA Czechia Turkey Slovakia Lithuania Russia Georgia* Poland Latvia Source: https://stats.oecd.org/Index.aspx?QueryId= 51882; NCDC Lithuania Russia Georgia *Cancer population registry, 5 year survival rate for patients diagnosed in 2015 High survival rate Average survival rate Low survival rate 12 Table 4.
Five-year survival rates of cancer by sites (%): colorectal cancer, trachea, bronchus and lung, 15 years and older, both sexes, 2010-2014 National Center for Disease Control and Public Health Trachea, bronchus, lung (both sexes) Japan 32.9 Israel Korea Canada USA Switzerland Iceland China Austria Sweden Australia Germany Latvia Belgium Norway Ireland Netherlands France Estonia Denmark Italy Portugal New Zealand Turkey Slovenia Poland 26.6 25.1 21.3 21.2 20.4 20.2 19.8 19.7 19.5 19.4 18.3 18.3 18.2 18.1 17.5 17.3 17.3 16.9 16.6 15.9 15.7 15.3 14.9 14.8 14.4 Russia Finland Georgia* Spain United Kingdom 13.7 13.5 13.3 13.0 12.3 11.2 10.6 9.9 Source: https://stats.oecd.org/Index.aspx?QueryId= 51882; NCDC Slovakia Czechia Lithuania Colorectal (both sexes) Australia Israel Korea Iceland Japan Canada USA Belgium Sweden Switzerland Finland Norway New Zealand Germany France Italy Netherlands Austria Spain Portugal United Kingdom Slovenia Ireland China Turkey Estonia Lithuania Poland Slovakia Latvia Czechia Denmark Russia Georgia* *Cancer population registry, 5 year survival rate for patients diagnosed in 2015 High survival rate Average survival rate Low survival rate 13 Table 5.
Five-year survival rates of cancer by sites (%): stomach and acute lymphoblastic leukemia, 15 year and older, both sexes, 2010-2014 National Center for Disease Control and Public Health Stomach (both sexes) Korea Japan Belgium China Austria Germany USA Israel Portugal Switzerland Australia Italy Canada Estonia Slovenia Iceland Ireland Spain Lithuania France Norway Finland Latvia Netherlands Sweden Turkey Slovakia Russia Poland United Kingdom Georgia* Acute lymphoblastic leukemia 95.2 Finland Denmark Canada Iceland United Kingdom Germany Belgium Australia Netherlands Switzerland United States Sweden France Ireland Czech republic Israel Italy Estonia Japan New Zealand Slovakia Poland Spain Korea Greece Latvia Norway Turkey Russia Lithuania Brasil China Georgia* Source: https://stats.oecd.org/Index.aspx?QueryId= 51882; NCDC Czechia Denmark * Cancer population registry, 5 year survival rate for patients diagnosed in 2015 High survival rate Average survival rate Low survival rate 14 Table 6.5 Five-year survival rates of cancer by sites (%), both sexes, Georgia F 13, 2015-2019 National Center for Disease Control and Public Health All sites Thyroid gland In situ Hodgkin's lymphoma Kidney and renal pelvis Corpus uteri Other skin cancers Breast (females) Bladder Cervix uteri Larynx Non-Hojkinis lymphoma Prostate Leukemia Mesothelial and soft tissues Colorectal cancer Ovary Melanoma Bone and articular cartilage Brain Stomach Trachea, bronchus, lung Pancreas Liver and intrahepatic bile ducts Five-year survival rate, % 50.1 Including: 92.8 89.1 74.5 69.3 66.7 66.5 66.0 56.9 56.9 50.8 47.9 46.6 43.9 43.2 41.4 39.1 37.7 37.7 33.5 22.7 12.3 12.0 11.7 According to the Cancer Population Register, early diagnosis of cancer is positively correlated with the five-year survival rates.
When cancer is diagnosed at late stages, the survival rate of decreases.

Figure 5.

Five-year survival rates of cancer by stages, Georgia.
2015-2019 13 Cancer population registry, 5 year survival rate for patients diagnosed in 2015 15 AGE AND SEX STRUCTURE National Center for Disease Control and Public Health In 2019, in Georgia, a total of 10,339 new cases of cancer of all sites were registered (incidence per 100,000 population - 277.9), including 4,578 cases (44.3%) - in men and 5,761 cases (55.7%) - in women.

Figure 6.
Figure 6.

Distribution of all sites of cancer by sex, Georgia, 2019 68% of new cases are registered in the most able-bodied age group (30-70 years), and 28% of cases - in the age group of 70 years and older.

1% of new cases are from the age groups of 0 - 14 years and 15 - 19 years.

Quarter (25%) of new cancers registered in women are from the group of reproductive age (15-49 years).

Figure 7.
Figure 7.

Cancers of all sites by age groups, Georgia, 2019 1% 3% 28% <20 20-29 30-69 70+ 68% 16 STAGES National Center for Disease Control and Public Health In 2019, 43% of new cases of cancer of all sites (except malignant neoplasms of lymphoid, hematopoietic and related tissues) of both sexes were registered at the I and II stages, at the III and IV - 41%, while for the rest cases the stage was not identified.

Figure 8.
Figure 8.

Cancers of all sites by stages (except malignant neoplasms of lymphoid, hematopoietic and related tissues, Georgia, 2019 17 TOP 5 SITES OF CANCER IN FEMALES Table 7.
New cases of cancer, females, Georgia, 2019 National Center for Disease Control and Public Health Site All sites Breast Thyroid gland Skin cancers, other than melanoma Colorectal Corpus uteri Cervix uteri Ovary Leukemia Stomach Bladder Kidney and renal pelvis Brain Pancreas Mesothelial and soft tissues Lymphoma, other than non-Hodgkin’s lymphoma Trachea, bronchus, lung Hepatic and intrahepatic biliary tract Bone and articular cartilage In situ Melanoma Hodgkin's lymphoma Non-Hodgkin's lymphoma Larynx Other sites Number of new cases 5587 % Table 8.
Top 5 cancers, females, Georgia, 2019 Site Breast Thyroid gland Colorectal Corpus uteri Cervix uteri All sites Number of new cases 1629 855 335 327 322 5587 Incidence per 100000 females 84,4 44,3 17,4 16,9 16,7 289,5 18 1.

BREAST CANCER IN FEMALES National Center for Disease Control and Public Health In 2019, in Georgia, there were 1629 new cases of breast cancer in women registered.

This is 28% of all new cases registered in this sex group.
The five-year survival rate for breast cancer in women diagnosed in 2015 was 66%.

According to the American National Cancer Institute estimates, the lifetime risk of developing breast cancer in American women is 12.9%14.

Table 9.
Table 9.

Breast cancer in females, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 females Mortality per 100000 females 2015 2016 2017 2018 2019 2044 32.9 105.1 31.2 1875 31.0 96.5 36.0 1783 31.3 91.9 36.5 1735 29.5 89.6 36.6 1629 28.3 84.4 38.2 During 2015-2019, the incidence of breast cancer was declining, according to the number of registered cases, there is a 20% decrease over the last 5 years.
The same time the breast cancer mortality increased by 23%.

Figure 9.

Breast cancer in females, incidence and mortality rates, Georgia 14 https://seer.cancer.gov/statfacts/html/breast.html 19 Figure 10.

Breast cancer in females, incidence per 100000 females15 National Center for Disease Control and Public Health Figure 11.
Breast cancer in females, mortality rate per 100000 females Source: WHO HFA DB, NCDC The age-specific incidence of breast cancer increases with the age and reaches its maximum at the age of 60-69 years.

Source: WHO HFA DB, NCDC 15 In 2015, Population Cancer Registry was introduced in Georgia 20 Figure 12.

Breast cancer in females, age-specific incidence rate per 100000 females, Georgia, 2019 National Center for Disease Control and Public Health 250 200 150 100 50 0 Table 10.
Breast cancer in females, distribution of new cases by age groups, Georgia Age 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Total Figure 13.
Breast cancer in females, distribution of new cases by stages, Georgia National Center for Disease Control and Public Health 2.

THYROID GLAND CANCER IN FEMALES In 2019, in Georgia, there were 855 new cases of thyroid gland cancer in women registered.

This is 14.8% of all new cases registered in this sex group.

The five-year survival rate for thyroid cancer in women diagnosed in 2015 was 92.8%.
According to the American National Cancer Institute estimates, the lifetime risk of developing thyroid gland cancer in American women is 1.3%16.
Table 11.Thyroid gland cancer in females, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 females Mortality per 100000 females 2015 2016 2017 2018 2019 607 9.8 31.2 1.1 784 12.9 40.4 1.8 785 13.8 40.5 1.0 929 15.8 48.0 1.6 855 14.8 44.3 1.7 16 https://seer.cancer.gov/statfacts/html/thyro.html 22 Figure 14.
Thyroid gland cancer in females, incidence and mortality rates, Georgia National Center for Disease Control and Public Health During 2015-2019, the incidence of thyroid gland cancer was raising, according to the number of registered cases, although, in 2019, there is a 9% decrease.

The same time the thyroid gland cancer mortality is stable.

The age-specific incidence of thyroid gland cancer iin females reaches its maximum at the age of 44-44 years.

Figure 15.
Figure 15.

Thyroid gland cancer in females, age-specific incidence rate per 100000 females, Georgia, 2019 120 100 80 60 40 20 0 23 Unlike other malignant neoplasms (except hematopoietic cancers), new cases of thyroid cancer have been reported in girls under-20 years of age.

National Center for Disease Control and Public Health Table 12.
Thyroid gland cancer in females, distribution of new cases by age groups, Georgia Age 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Total Table 16.
Thyroid gland cancer in females, distribution of new cases by stages, Georgia 24 3.

COLORECTAL CANCER IN FEMALES National Center for Disease Control and Public Health In 2019, in Georgia, there were 355 new cases of colorectal cancer in women registered.

This is 5.8% of all new cases registered in this sex group.

The five-year survival rate for colorectal cancer in women diagnosed in 2015 was 41.4%.
According to the American National Cancer Institute estimates, the lifetime risk of developing colorectal cancer in American women is 4.2%1 17.

Table 13.

Colorectal cancer in females, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 females Mortality per 100000 females 2015 2016 2017 2018 2019 420 6.8 21.6 10.2 377 6.2 19.4 12.0 329 5.8 17.0 11.3 367 6.2 19.0 14.3 335 5.8 17.4 13.6 Figure 17.
Colorectal cancer in females, incidence and mortality rates, Georgia During 2015-2019, the incidence of colorectal cancer was declining.

In 2019, the incidence rate per 10000 females was 17.4, the same time the colorectal cancer mortality is increasing and, in 2019, it reached 13.6 per 100000 females.

The age-specific incidence of colorectal cancer increases with the age and reaches its maximum at the age of 70-74 years.

17 https://seer.cancer.gov/statfacts/html/colorect.html 25 Figure 18.
Colorectal cancer in females, age-specific incidence rate per 100000 females, Georgia, 2019 National Center for Disease Control and Public Health 70 60 50 40 30 20 10 0 Table 14.
Colorectal cancer in females, distribution of new cases by age groups, Georgia Age 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Total Figure 19.
Colorectal cancer in females, distribution of new cases by stages, Georgia National Center for Disease Control and Public Health 4.

CORPUS UTERI CANCER In 2019, in Georgia, there were 327 new cases of corpus uteri cancer registered.

This is 5.7% of all new cases registered in women.

The five-year survival rate for corpus uteri cancer diagnosed in 2015 was 66.7%.

According to the American National Cancer Institute estimates, the lifetime risk of developing corpus uteri cancer in American women is 3.1%18.
Table 15.

Corpus uteri cancer, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 females Mortality per 100000 females 2015 2016 2017 2018 2019 369 5.9 19.0 4.8 373 6.2 19.2 6.2 344 6.0 17.7 6.6 372 6.3 19.2 7.4 327 5.7 16.9 7.9 18 https://seer.cancer.gov/statfacts/html/corp.html 27 Figure 20.
Corpus uteri cancer, incidence and mortality rates, Georgia National Center for Disease Control and Public Health In 2015-2018, the incidence of corpus uteri cancer remained stable, ialthough, In 2019, the incidence decreased to 16.9 per 100,000 women.

During the same period, the mortality rate from corpus uteri cancer was steadily increasing, and, in 2019 the rate reached 7.9 per 100,000 women.

The age-specific incidence of corpus uteri cancer ireaches its maximum at the age of 60–69 years.

Figure 21.
Figure 21.

Corpus uteri cancer, age-specific incidence rate per 100000 females, Georgia, 2019 60 50 40 30 20 10 0 28 Table 16.
Corpus uteri cancer, distribution of new cases by age groups, Georgia National Center for Disease Control and Public Health Age 20-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 60-69 70-74 75+ Total Figure 22.
Corpus uteri cancer, distribution of new cases by stages, Georgia CERVIX UTERI CANCER In 2019, in Georgia, there were 322 new cases of cervix uteri cancer registered.

This is 5.6% of all new cases registered in women.

The five-year survival rate for cervix uteri cancer diagnosed in 2015 was 56.9%.

According to the American National Cancer Institute estimates, the lifetime risk of developing cervix uteri cancer in American women is 0.6%19.
19 https://seer.cancer.gov/statfacts/html/cervix.html 29 Table 17.

Cervix uteri cancer, incidence and mortality rates, Georgia, 2015-2019 National Center for Disease Control and Public Health New cases % of the total number of new cases Incidence per 100000 females Mortality per 100000 females 2015 2016 2017 2018 2019 357 5.8 18.4 8.5 406 6.7 20.9 6.2 308 5.4 15.9 8.1 291 4.9 15.0 8.6 322 5.6 16.7 8.5 Figure 23.

Cervix uteri cancer, incidence and mortality rates, Georgia Figure 24.
Cervix uteri cancer, incidence rate per 100000 females In 2015-2018, the incidence of cervix uteri cancer was declining.

In 2019, the incidence rate increased and reached 5.6 per 100,000 women.

During the same period, the mortality rate from cervix uteri cancer was increasing, and, in 2019, the rate reached 8.5 per 100,000 women.

The age-specific incidence of cervix uteri cancer reaches its maximum at the age of 50-54 years.
Source: WHO HFA DB, NCDC 30 National Center for Disease Control and Public Health Figure 25.

Cervix uteri cancer, age-specific incidence rate per 100000 females, Georgia, 2019 250 200 150 100 50 0 Table 18.
Cervix uteri cancer, distribution of new cases by age groups, Georgia Age 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Total Figure 26.
Cervix uteri cancer, distribution of new cases by stages, Georgia 31 TOP 5 SITES OF CANCER IN MALES Table 19.
New cases of cancer, males, Georgia, 2019 National Center for Disease Control and Public Health Site All sites Trachea, bronchus, lung Prostate Bladder Skin cancers, other than melanoma Colorectal Larynx Stomach Kidney and renal pelvis Hepatic and intrahepatic biliary tract Leukemia Thyroid gland Brain Pancreas Lymphoma, other than non-Hodgkin’s lymphoma Mesothelial and soft tissues Bone and articular cartilage Hodgkin's lymphoma in situ Melanoma Breast Non-Hodgkin's lymphoma Other sites Number of new cases 4578 623 548 405 402 376 215 206 188 151 147 142 121 82 63 45 43 27 26 24 23 23 698 % 100.0 13.6 12.0 8.8 8.8 8.2 4.7 4.5 4.1 3.3 3.2 3.1 2.6 1.8 1.4 1.0 0.9 0.6 0.6 0.5 0.5 0.5 15.2 Table 20.
Top 5 cancers, males, Georgia, 2019 Site Number of new cases Trachea, bronchus, lung Prostate Bladder Trachea, bronchus, lung Larynx All sites 623 548 405 376 215 4578 Incidence per 100000 females 34,8 30,6 22,6 21,0 12,0 255,7 1.

TRACHEA, BRONCHUS, LUNG IN MALES In 2019, in Georgia, there were 623 new cases of trachea, bronchus and lung cancer in men registered.

This is 13.6% of all new cases registered in this sex group.
According to international estimates, the most common cancers in men are malignant neoplasms of the trachea, bronchus and 32 lungs.

According to the American National Cancer Institute estimates, the lifetime risk of developing this cancer in American men is 6.3%1 20.

National Center for Disease Control and Public Health The five-year survival rate for trachea, bronchus, and lung cancer in men diagnosed in 2015 was 17.1%.

Table 21.
Table 21.

Trachea, bronchus and lung cancer in males, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 2016 2017 2018 2019 740 15.1 41.6 48.0 723 15.6 40.5 53.7 699 15.7 39.1 51.6 638 14.1 35.6 54.4 623 13.6 34.8 53.3 Figure 27.

Trachea, bronchus and lung cancer in males, incidence and mortality rates, Georgia 20 https://seer.cancer.gov/statfacts/html/prost.html 33 Figure 28.
Trachea, bronchus and lung cancer in males, mortality rate per 100000 males National Center for Disease Control and Public Health Figure 29.

Trachea, bronchus and lung cancer in males, incidence rate per 100000 males Source: WHO HFA DB, NCDC During 2015-2019, the incidence of trachea, bronchuss and lung cancer in men was declining, and, in 2019, it reached 34.8 per 100000 males.

The same time the mortality due to trachea, bronchuss and lung cancer increased and, in 2019, it reached 53.3.
Source: WHO HFA DB, NCDC 34 The age-specific incidence of trachea, bronchuss and lung cancer reaches its maximum at the age of 60-69 years.

National Center for Disease Control and Public Health Figure 30.

Trachea, bronchus and lung cancer in males, age-specific incidence rate per 100000 males, Georgia, 2019 180 160 140 120 100 80 60 40 20 0 Table 22.
Trachea, bronchus and lung cancer in males, distribution of new cases by age Age 20-24 20-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 60-69 70-74 75+ Total groups, Georgia Figure 31.
Trachea, bronchus and lung cancer in males, distribution of new cases by stages, Georgia National Center for Disease Control and Public Health 2.

PROSTATE CANCER In 2019, in Georgia, there were 548 new cases of prostate cancer registered.

This is 12% of all new cases registered in this sex group.

The five-year survival rate for prostate cancer diagnosed in 2015 was 46.6%.
According to the American National Cancer Institute estimates, the lifetime risk of developing this cancer in American men is 12.1%0F 21.

Table 23.

Prostate cancer, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 2016 2017 2018 2019 638 13.0 35.8 15.7 506 10.9 28.4 18.7 477 10.7 26.7 20.4 560 12.4 31.3 21.2 548 12.0 30.6 27.5 21 https://seer.cancer.gov/statfacts/html/prost.html 36 Figure 32.
Prostate cancer, incidence and mortality rates, Georgia National Center for Disease Control and Public Health Figure 33.

Prostate cancer, mortality rate per 100000 males During 2015-2019, the incidence of prostate cancer was declining, and, in 2019, it reached 30.6 per 100000 males.

The same time the mortality due to prostate cancer sharply increased and, in 2019, it reached 27.5.

The age-specific incidence of prostate cancer reaches its maximum at the age of 70-74 years.
Source: WHO HFA DB, NCDC 37 Figure 34.

Prostate cancer, age-specific incidence rate per 100000 males, Georgia, 2019 National Center for Disease Control and Public Health 250 200 150 100 50 0 Table 24.
Prostate cancer, distribution of new cases by age groups, Georgia Age 5-9 15-19 30-34 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Total Figure 35.
Prostate cancer distribution of new cases by stages, Georgia 38 National Center for Disease Control and Public Health 3.

BLADDER CANCER IN MALES In 2019, in Georgia, there were 405 new cases of bladder cancer registered in men.

This is 8.8% of all new cases registered in this sex group.

The five-year survival rate for prostate cancer diagnosed in 2015 was 56.2%.

According to the American National Cancer Institute estimates, the lifetime risk of developing this cancer in American men is 2.4%21F 22.
Table 25.

Bladder cancer in males, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 2016 2017 2018 2019 436 8.9 24.5 8.0 414 8.9 23.2 10.1 454 10.2 25.4 11.5 405 8.9 22.6 12.8 405 8.8 22.6 12.1 Figure 36.

Bladder cancer in males, incidence and mortality rates, Georgia 22 https://seer.cancer.gov/statfacts/html/urinb.html 39 Figure 37.
Bladder cancer in males, mortality rate per 100000males National Center for Disease Control and Public Health Source: WHO HFA DB, NCDC During 2015-2019, the incidence of bladder cancer in males was stable, and, in 2019, it reached 22.6 per 100000 males.

The same time the mortality due to bladder cancer was increasing and, in 2019, it reached 12.1 per 100000 males.

The age-specific incidence of prostate cancer reaches its maximum at the age of 60-65 and 70 and older years.

Figure 38.
Figure 38.

Bladder cancer in males, age-specific incidence rate per 100000 males, Georgia, 2019 120 100 80 60 40 20 0 40 Table 26.
Bladder cancer in males, age-specific incidence rate per 100000 males, Georgia National Center for Disease Control and Public Health Age 0-4 10-14 15-19 20-24 20-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 60-69 70-74 75+ Total Figure 39.
Bladder cancer distribution of new cases by stages, Georgia 41 National Center for Disease Control and Public Health 4.

COLORECTAL CANCER IN MALES In 2019, in Georgia, there were 376 new cases of colorectal cancer registered in men.

This is 8.2% of all new cases registered in this sex group.

The five-year survival rate for prostate cancer diagnosed in 2015 was 40.3%.

According to the American National Cancer Institute estimates, the lifetime risk of developing this cancer in American men is 4.2%2F 23.
Table 27.

Colorectal cancer in males, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 422 8.6 23.7 12.7 2016 415 8.9 23.3 15.1 2017 417 9.3 23.3 15.9 2018 404 8.9 22.6 16.6 2019 376 8.2 21.0 19.2 Figure 40.

Colorectal cancer in males, incidence and mortality rates, Georgia During 2015-2019, the incidence of colorectal cancer in males was decreasing, and, in 2019, it reached 21.0 per 100000 males.
The same time the mortality due to colorectal cancer in males was increasing and, in 2019, it reached 19.6 per 100000 males.

The age-specific incidence of colorectal cancer in males reaches its maximum at the age of 70-74 years.

23 https://seer.cancer.gov/statfacts/html/colorect.html 42 Figure 41.

Colorectal cancer in males, age-specific incidence rate per 100000 males, Georgia, 2019 National Center for Disease Control and Public Health 120 100 80 60 40 20 0 Table 28.
Colorectal cancer in males, age-specific incidence rate per 100000 males, Georgia Age 0-4 10-14 20-24 20-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 60-69 70-74 75+ Total Table 42.
Colorectal cancer distribution of new cases by stages, Georgia National Center for Disease Control and Public Health 5.

LARINX CANCER IN MALES In 2019, in Georgia, there were 215 new cases of larynx cancer registered in men.

This is 4.7% of all new cases registered in this sex group.

The five-year survival rate for prostate cancer diagnosed in 2015 was 50.8%.

According to the American National Cancer Institute estimates, the lifetime risk of developing this cancer in American men is 0.3%3F 24.
Table 29.

Larynx cancer in males, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 2016 2017 2018 2019 306 6.3 17.2 7.8 289 6.2 16.2 8.6 263 5.9 14.7 8.7 247 5.5 13.8 9.2 215 4.7 12.0 9.7 24 https://seer.cancer.gov/statfacts/html/laryn.html 44 Figure 43.
Larynx cancer in males, incidence and mortality rates, Georgia National Center for Disease Control and Public Health During 2015-2019, the incidence of larynx cancer in males was decreasing, and, in 2019, it reached 12.0 per 100000 males.

The same time the mortality due to colorectal cancer in males was increasing and, in 2019, it reached 9.7 per 100000 males.

The age-specific incidence of colorectal cancer in males reaches its maximum at the age of 55-59 years.

Figure 44.
Figure 44.

Larynx cancer in males, age-specific incidence rate per 100000 males, Georgia, 2019 50 45 40 35 30 25 20 15 10 5 0 45 Table 30.
Larynx cancer in males, age-specific incidence rate per 100000 males, National Center for Disease Control and Public Health Age 20-24 30-34 35-39 40-44 45-49 50-54 55-59 60-64 60-69 70-74 75+ Total Georgia Figure 45.
Larynx cancer distribution of new cases by stages, Georgia 46 CANCER IN EARLY AGES National Center for Disease Control and Public Health Incidence rates are strongly related to age for all cancers combined, with the highest incidence rates being in older people.

Some types of cancer are more common in children or adolescents than in adults.

In 2019, in Georgia, a share of new cases registered in early age (under-20) is 1.3% of new cases of cancer registered in all age groups.
Treatment of cancer in children is often more successful and better adheres to certain methods t. This can be explained by the different types of malignant neoplasms in children, the absence of concomitant diseases that aggravate the condition of adult cancer patients, and often reduce the effectiveness of treatment25.

The five-year survival rate of new cases registered in 2015 at early ages (under-20) is high - 93% for both sexes.
MALIGNANT NEOPLASMS IN CHILDREN AGED UNDER-15 During 2015-2019, the incidence of cancer in children was increasing, and, in 2019, it reached 11.4 per 100000 children (total of 86 cases).

Table 31.
Table 31.

Cancer in children aged under-15, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 92 0.8 12.9 2.7 2016 101 0.9 13.9 3.3 2017 86 0.8 11.8 3.7 2018 76 0.7 10.1 2.8 2019 86 0.8 11.4 2.6 In 2019, in Georgia, there were 38 new cases of cancer registered in girls aged under-15, incidence rate per 100000 girls – 10.5, this is about 13% less than the number of cases in boys of the same age.
In 2019, in Georgia, there were 48 new cases of cancer registered in boys aged under-15, incidence rate per 100000 boys – 12.2.

The five-year survival rate of cancers, diagnosed, in 2015, was higher in boys (94%), compared to girls (92%).

25 https://www.cancer.org/cancer/cancer-in-young-adults/finding-cancer-in-young-adults.html 47 Figure 46.
Five-year survival rate of cancers (%) in the age group under-15 by sex, Georgia National Center for Disease Control and Public Health In children, for both sexes hematopoietic cancer accounts for the largest share among all sites.

Figure 47.
Figure 47.

New cases of cancer, percent distribution in children aged under-15, both sexes, Georgia During last 5 years in Georgia, lymphoid leukemia and thyroid cancer are the leading sites of cancer in girls aged under-15 years, accounting for about 50% of the cases registered in this age and sex group.

More than 80% of cases in boys are brain cancer and leukemia.
48 MALIGNANT NEOPLASMS IN ADOLESCENTS AGED 15–19 YEARS National Center for Disease Control and Public Health The incidence of different types of cancer is characterized by age-related variability, with malignant neoplasms such as Hodgkin's lymphoma, testicular cancer, and sarcoma being more common in adolescents and less common for children and adults.

Last 5 years, the incidence rate of new cases of cancer of all sites in the age group of 15-19 years of age is about 22 per 100,000 per relevant population.
Table 32.

Cancer in adolescents aged 15-19, incidence and mortality rates, Georgia, 2015-2019 New cases % of the total number of new cases Incidence per 100000 males Mortality per 100000 males 2015 2016 2017 2018 2019 56 0.5 25.0 4.9 43 0.4 19.2 2.7 57 0.6 25.4 4.2 41 0.4 18.3 5.8 49 0.5 21.9 5.4 In 2019, in Georgia, there were 27 new cases of cancer registered in young women aged 15-19 years, incidence rate per 100000 female – 28.0, this is 27.8% higher than the number of cases in males of the same age.
In 2019, in Georgia, there were 22 new cases of cancer registered in males aged 15, incidence rate per 100000 males – 20.2.

The five-year survival rate of cancers, diagnosed in this age group in 2015, in females is 100%, in males – 86%.

Figure 48.

Five-year survival rate of cancers (%) in the age group 15 – 19 years by sex, Georgia In adolescents, for both sexes thyroid gland cancer accounts for the largest share among all sites, this is caused by the cases registered in females.

49 Figure 49.
49 Figure 49.

New cases of cancer, percent distribution in adolescents aged 15-19, both sexes, Georgia National Center for Disease Control and Public Health According to 2019 data, thyroid cancer is the leading malignant neoplasm in young women aged 15–19 years and accounts for more than 50% of new cases registered in this age-sex group.

In boys, 40% of cases are due to hematopoietic cancer.

In the 15-19 age group, more than 50% of new cases of cancer of all sites are registered at stage I.

Figure 50.
Cancer, new cases in adolescents aged 15-19, by stages 25F 26 in percent, both sexes, Georgia 26 Except malignant neoplasms of lymphoid, hematopoietic and related tissues 50 National Center for Disease Control and Public Health GEOGRAPHIC DISTRIBUTION The Cancer Population Register collects personalized data, which include a patients’ demographic characteristics, including the patients’ place of residence, various specific characteristics of the disease, and location of medical care provider, allowing geographic assessment of cancer-related morbidity and possible clusters of high disease concentrations.
Table 33.
Cancer, distribution of new cases by regions of Georgia (patient's place of residence) Abkhazia Ajara Guria Tbilisi Imereti Kakheti Mtskheta-Mtianeti Racha-Lechkhumi and Kvemo Svaneti Samegrelo and Zemo Svaneti Samtskhe-Javakheti Kvemo Kartli Shida Kartli Unknown Georgia Cancer clusters are defined as concentration of more than expected cases of cancer of the same site or similar etiology, which are manifested in a specific period of time and in specific population groups in a given settlement (common age group, impact of similar occupational factors, etc.).
Age-standardized (age-adjusted) incidence rates were used to detect cancer clusters, this helped avoiding variability due to age structure differences between geographical points (e.g., an increased number of the aged population, which is increasing crude morbidity of cancer).

Age standardization involves rearranging of different populations to the same age structure.

In this case, the variation in the age-standardized morbidity rate between regions only indicates different intensities of risk factors.
The age distribution of the population of Georgia was selected as a comparable age structure of the population for the regions.

51 Table 34.
51 Table 34.

Cancer, crude and age-standardized incidence rates per 100,000 population National Center for Disease Control and Public Health Crude incidence Ajara Guria Tbilisi Imereti Kakheti Mtskheta-Mtianeti Racha-Lechkhumi and Kvemo Svaneti Samegrelo and Zemo Svaneti Samtskhe-Javakheti Kvemo Kartli Shida Kartli Georgia 267.4 320.0 292.8 257.8 242.9 283.5 316.4 230.5 184.8 204.7 278.3 277.9 27 Age-standardized incidence26F 299.1 281.3 317.2 242.4 228.4 270.5 253.3 212.2 190.1 225.9 272.5 277.9 Map 1.
Age-standardized incidence per 100,000 population, municipalities of Georgia, 2019 27 The structure of the mid-year population of Georgia in 2019 is used 52 Table 35.
Cancer, crude and age-standardized incidence rates per 100,000 population, by municipalities, Georgia, 2019 National Center for Disease Control and Public Health Abasha Adigeni Ambrolauri Aspindza Akhalkalaki Akhaltsikhe Akhmeta Batumi Baghdati Bolnisi Borjomi Gardabani Gori Gurjaani Dedoplistskaro Dmanisi Dusheti Vani Zestafoni Zugdidi Tbilisi Tetritskaro Telavi Terjola Tianeti Kaspi Lagodekhi Lanchkhuti Lentekhi Marneuli Simple Mestia Mtskheta Ninotsminda Ozurgeti Oni Rustavi Sagarejo Samtredia Sachkhere Crude incidence Age-standardized incidence26F The structure of the mid-year population of Georgia in 2019 is used 53 Senaki Signagi Tkibuli Poti Kareli Ridge Kobuleti Kutaisi Kazbegi Kvareli Shuakhevi Chokhatauri Chkhorotsku Tsageri Tsalenjikha Tsalka Tskaltubo Chiatura Kharagauli Khashuri Khelvachauri Khobi Khoni Khulo National Center for Disease Control and Public Health Above average value Average value Below average value 54 SCREENING OF CANCER National Center for Disease Control and Public Health Since 2011, the following cancer screening programs have been implemented in the country: • Breast cancer screening for 40-70-year-old women; • Cervical cancer screening for 25-60-year-old women; • Prostate cancer management for 50-70-year-old men; • Colorectal cancer screening for 50-70-year-old population.
Figure 51.

Cancer screening rates, target population (%), Georgia29 29The State program for regions was launched on May 1, 2011, thus, 2011 data cover only 8 months 55 National Center for Disease Control and Public Health TREATMENT Coincided data from the Cancer Population Register and the Social Services Agency database were used to describe treatment methods of malignant neoplasms.

Table 36.
Table 36.

Treatment methods of all sites of cancer, both sexes, all age groups, Georgia, 2019 Methods of treatment Number of patients treated Surgical treatment Chemiatherapy and hormone therapy Radiotherapy .iodine therapy Palliative treatment Immunotherapy 7316 5520 2736 529 336 63 Percent of the total number of patients 70.8 53.4 26.5 5.1 3.2 0.6 Table 37.
Surgical operations by site of cancer, both sexes, 2019 Site Total number of patients Number of patients treated Percent of the total number of patients Total Breast Thyroid gland Colorectal cancer Trachea, bronchus, lung Prostate Bladder Corpus uteri Stomach Cervix uteri Ovary brain Larynx Lip, mouth and throat Pancreas Soft tissue Bone and articular cartilage Multiple myeloma Hodgkin's lymphoma Melanoma Non-Hojkin lymphoma In situ Including: 1652 997 711 697 548 515 327 322 322 279 267 223 219 160 121 85 79 50 47 45 66 56 TREATMENT: TOP 5 SITES OF CANCER IN FEMALES National Center for Disease Control and Public Health In 2019, surgical interventions constituted the largest share among treatment methods of the top 5 sites of cancer registered in women.
Surgical operations are used in 89% of new cases of breast cancer in women.

Table 38.
Breast cancer in females, new treatment methods distribution (%), Georgia, 2019 Total number of new cases of breast cancer in females - 1629 Methods of treatment Number of patients treated Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 1221 745 1453 Percent of the total number of patients 75,0 45,7 89,2 In 2019, 1453 women had got surgery for breast cancer, this is 89% of women registered with breast cancer diagnosis; including, 57% of patients - in stages I and II of the disease.
Surgery was performed on 72% of patients diagnosed at stages III and IV of the disease.

Table 39.

Breast cancer in women, share of surgical treatment (%) by stages, Georgia, 2019 Stage 0 Stage I Stage II Stage III Stage IV Unknown Total number of patients 4 302 508 347 182 286 Percent of treated patients 100.0 98.3 99.8 99.4 19.8 92.3 Figure 52.
Breast cancer in women, share of surgical treatment (%) by stages, Georgia, 2019 57 Among patients with thyroid gland cancer, 92% received surgical treatment and 50% - iodine therapy.

National Center for Disease Control and Public Health Table 40.
Thyroid gland cancer in females, treatment methods distribution (%), Georgia, 2019 Total number of new cases of thyroid gland cancer in females - 855 Methods of treatment Number of patients treated Percent of the total number Iodine therapy Radiotherapy Surgical treatment 423 13 783 of patients 49.5 1.5 91.6 Figure 41.
Thyroid gland cancer in females, share of surgical treatment (%) by stages, Georgia, 2019 Stage I Stage II Stage III Stage IV Unknown Total number of patients 752 42 20 14 27 Percent of treated patients 92.8 85.7 65.0 57.1 92.6 In 2019, 783 women had got thyroid gland surgery, including 94% at stages I and II.

Figure 53.

Thyroid gland cancer in women, share of surgical treatment (%) by stages, Georgia, 2019 58 Among women with new cases of colorectal cancer, 84% received surgical treatment.
National Center for Disease Control and Public Health Table 42.

Colorectal cancer in females, treatment methods distribution (%), Georgia, 2019 Total number of new cases of colorectal cancer in females - 335 Methods of treatment Chemiatherapy and hormone therapy Number of patients treated 229 Percent of the total number of patients 68,4 Radiotherapy Surgical treatment 62 282 18,5 84,2 Table 43.
Colorectal cancer in women, share of surgical treatment (%) by stages, Georgia, 2019 Total number of patients Stage I Stage II Stage III Stage IV Unknown 26 66 115 70 58 Percent of treated patients 76.9 92.4 92.2 64.3 82.8 In 2019, 282 women had got surgery due to colorectal cancer, including 28% at stages I and II.

Figure 54.

Colorectal cancer in women, share of surgical treatment (%) by stages, Georgia, 2019 59 Among women with new cases of corpus uteri cancer, 95% received surgical treatment.
National Center for Disease Control and Public Health Table 44.

Corpus uteri cancer, treatment methods distribution (%), Georgia, 2019 Total number of new cases of corpus uteri cancer - 327 Methods of treatment Chemiatherapy and hormone therapy Radiotherapy Surgical treatment Number of patients treated 102 155 296 Percent of the total number of patients 31.2 47.4 90.5 Table 45.
Corpus uteri cancer, share of surgical treatment (%) by stages, Georgia, 2019 Stage I Stage II Stage III Stage IV Unknown Total number of patients 154 44 51 18 60 Percent of treated patients 94.2 97.7 92.2 38.9 90.0 In 2019, 296 women had got surgery due to corpus uteri cancer, including 63% at stages I and II.

Figure 55.
Figure 55.

Corpus uteri cancer, share of surgical treatment (%) by stages, Georgia, 2019 60 Among women with new cases of cervix uteri cancer, 96% received chemotherapy or hormone therapy, 79% received surgical treatment.

National Center for Disease Control and Public Health Table 46.
Cervix uteri cancer, treatment methods distribution (%), Georgia, 2019 Total number of new cases of cervix uteri cancer - 322 Methods of treatment Number of patients treated Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 310 287 253 Percent of the total number of patients 96.3 89.1 78.6 Table 47.
Cervix uteri cancer, share of surgical treatment (%) by stages, Georgia, 2019 Stage I Stage II Stage III Stage IV Unknown Total number of patients 76 84 86 44 32 Percent of treated patients 98.7 85.7 84.9 22.7 71.9 In 2019, 253 women had got surgery due to cervix uteri cancer, including 61% at stages I and II.

Figure 56.
Figure 56.

Cervix uteri cancer, share of surgical treatment (%) by stages, Georgia, 2019 61 National Center for Disease Control and Public Health TREATMENT: TOP 5 SITES IN MALES Surgical operations are used in 37% of new cases of trachea, bronchus and lung cancer in men.

Table 48.
Table 48.

Trachea, bronchus and lung cancer in males, treatment methods distribution (%), Georgia, 2019 Total number of new cases of trachea, bronchus and lung cancer in males - 623 Methods of treatment Number of patients treated Percent of the total number of Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 406 214 233 patients 65,2 34,3 37,4 Table 49.
Trachea, bronchus and lung cancer in males, share of surgical treatment (%) by stages, Georgia, 2019 Total number of patients Stage I Stage II Stage III Stage IV Unknown 7 37 163 342 74 Percent of treated patients 85.7 56.8 44.2 28.9 47.3 Cancer at the stage IV has got the largest share of surgeries performed due to trachea, bronchus and lung cancer in men Figure 57.
Trachea, bronchus and lung cancer in males, share of surgical treatment (%) by stages, Georgia, 2019 62 Among patients with prostate cancer, 65% received chemotherapy / hormone therapy and 51% received surgical treatment.

National Center for Disease Control and Public Health Table 50.
Prostate cancer, treatment methods distribution (%), Georgia, 2019 Total number of new cases of prostate cancer - 548 Number of patients treated Number of patients treated Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 358 90 278 Number of patients treated 65.3 16.4 50.7 Table 51.
Prostate cancer, share of surgical treatment (%) by stages, Georgia, 2019 Total number of patients 50 138 112 196 52 Percent of treated patients 60.0 83.3 53.6 25.0 46.2 Stage I Stage II Stage III Stage IV Unknown In 2019, 278 men had got surgery due to prostate cancer, including 53% at stages I and II.

Figure 58.

Prostate cancer share of surgical treatment (%) by stages, Georgia, 2019 Surgical operations are used in 90% of new cases of bladder cancer in men.

63 Table 52.
63 Table 52.

Bladder cancer in males, treatment methods distribution (%), Georgia, 2019 National Center for Disease Control and Public Health Total number of new cases of bladder cancer in males - 405 Methods of treatment Number of patients treated Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 236 14 363 Percent of the total number of patients 58.3 3.5 89.6 Table 53.
Bladder cancer in males, share of surgical treatment (%) by stages, Georgia, 2019 Stage I Stage II Stage III Stage IV Unknown Total number of patients 171 111 46 23 54 Percent of treated patients 93.0 89.2 78.3 65.2 100.0 In 2019, 363 men had got surgery due to bladder cancer, including 70% at stages I and II.

Figure 59.
Figure 59.

Bladder cancer in males, share of surgical treatment (%) by stages, Georgia, 2019 64 In 2019, 78% of men with new cases of colorectal cancer had got surgery and 67% - chemia therapy / hormone therapy.

National Center for Disease Control and Public Health Table 54.
Colorectal cancer in men, share of surgical treatment (%) by stages, Georgia, 2019 Total number of new cases of colorectal cancer in males - 376 Methods of treatment Number of patients treated Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 250 73 307 Percent of the total number of patients 66.5 19.4 77.9 Table 55.
Colorectal cancer in men, share of surgical treatment (%) by stages, Georgia, 2019 Stage I Stage II Stage III Stage IV Unknown Total number of patients 15 68 128 72 93 Percent of treated patients 80.0 82.4 86.7 66.7 71.0 In 2019, 307 men had got surgery due to colorectal cancer, including 24% at stages I and II.

Figure 60.
Figure 60.

Colorectal cancer in men, share of surgical treatment (%) by stages, Georgia, 2019 65 Surgical operations are used in 76% of new cases of larynx cancer in men, in 63% chemotherapy / hormone therapy are used.

National Center for Disease Control and Public Health Table 56.
Larynx cancer in males, treatment methods distribution (%), Georgia, 2019 Total number of new cases of larynx cancer in males - 215 Methods of treatment Number of patients treated Percent of the total number of patients Chemiatherapy and hormone therapy Radiotherapy Surgical treatment 136 211 164 63.3 98.1 76.3 Table 57.
Larynx cancer in males, share of surgical treatment (%) by stages, Georgia, 2019 Total number of patients 41 21 80 57 16 Percent of treated patients 48.8 52.4 82.5 100.0 62.5 Stage I Stage II Stage III Stage IV Unknown In 2019, 164 men had got surgery due to larynx cancer, including 18% at stages I and II.

Figure 61.
Figure 61.

Larynx cancer share of surgical treatment (%) by stages, Georgia, 2019 66 National Center for Disease Control and Public Health The booklet is prepared by the Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs and the Department of Medical Statistics of the National Center for Disease Control and Public Health named after L.Sakvarelidze.
The published materials may be freely used and no permission for reproduction in part or in whole is needed.

The NCDC welcomes mentioning as a source.

In any question applications, should be made to the National Center for Disease Control and Public Health named after L.Sakvarelidze at 99, Kakheti Highway, 0198, Tbilisi, Georgia E-mail: pr.ncdc@ncdc.ge Web-site: www.ncdc.ge Free of charge 67